Free Trial

Pacira BioSciences Q2 2023 Earnings Report

Pacira BioSciences logo
$22.36 +0.30 (+1.36%)
As of 01/17/2025 04:00 PM Eastern

Pacira BioSciences EPS Results

Actual EPS
$0.61
Consensus EPS
$0.59
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Pacira BioSciences Revenue Results

Actual Revenue
$169.47 million
Expected Revenue
$175.64 million
Beat/Miss
Missed by -$6.17 million
YoY Revenue Growth
N/A

Pacira BioSciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Pacira BioSciences Earnings Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
See More Pacira BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email.

About Pacira BioSciences

Pacira BioSciences (NASDAQ:PCRX) is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

View Pacira BioSciences Profile

More Earnings Resources from MarketBeat